BNP Paribas Asset Management
AMPH icon

BNP Paribas Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

BNP Paribas Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-396
Closed -$7.76K – 2262
2026
Q1 		$7.76K Sell
396
-3,366
-89% -$82.3K ﹤0.01% 2252
2025
Q4 		$101K Buy
3,762
+3,582
+1,990% +$92.3K ﹤0.01% 1462
2025
Q3 		$5K Sell
180
-19
-10% -$491 ﹤0.01% 1811
2025
Q2 		$5K Buy
+199
New +$4.94K ﹤0.01% 1968

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

BNP Paribas Asset Management's AMPH Position: Q2 2026 in Review

BNP Paribas Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 396 shares — an estimated $7.76K sold.

BNP Paribas Asset Management first reported a position in AMPH in Q2 2025 and held it in 4 quarters. The position peaked at $101K in Q4 2025. 201 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • BNP Paribas Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 396 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $7.76K.
  • BNP Paribas Asset Management first reported a position in Amphastar Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • BNP Paribas Asset Management's Amphastar Pharmaceuticals position peaked at $101K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.